Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data

被引：0
|
作者：
Jorge Nieva
Karen L. Reckamp
Danielle Potter
Aliki Taylor
Ping Sun
机构：
[1] University of Southern California,Department of Medicine
[2] Norris Comprehensive Cancer Center,Department of Medicine
[3] Cedars Sinai Medical Center,Global Epidemiology, Oncology Business Unit, Global Medical Affairs
[4] AstraZeneca,Real World Science and Digital
[5] AstraZeneca,CancerLinQ LLC
[6] American Society of Clinical Oncology,undefined
来源：
Drugs - Real World Outcomes | 2022年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：333 / 345
页数：12
相关论文
共 50 条
  • [21] Osimertinib vs Comparator EGFR-TKI As First-Line Treatment for EGFRM Advanced NSCLC (Flaura): Final Overall Survival Analysis
    Reinmuth, Niels
    Bischoff, Helge
    Bohnet, Sabine
    Zum Bueschenfelde, Christian Meyer
    Rueckert, Antje
    Hodge, Rachel
    Rukazenkov, Yuri
    Ramalingam, Suresh S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 116 - 116
  • [22] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
    Ramalingam, S. S.
    Gray, J. E.
    Ohe, Y.
    Cho, B. C.
    Vansteenkiste, J.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M. C.
    Imamura, F.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    Planchard, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 914 - +
  • [23] Virtual patient simulation improves first-line treatment selection in advanced EGFR-mutated NSCLC
    Worst, Michelle A.
    Caracio, Rich
    Topping, Donna L.
    Ramalingam, Suresh S.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [24] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
    Cho, B. C.
    Ohe, Y.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Lee, K. H.
    Planchard, D.
    Vansteenkiste, J. F.
    Gray, J. E.
    Shah, R.
    Cheema, P. K.
    Tiseo, M.
    John, T.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    Lin, M-C.
    Imamura, F.
    Ramalingam, S. S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [25] Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
    Tian, P.
    Wu, L.
    Zhou, C.
    Tan, J.
    Wang, K.
    Luo, F.
    Liu, Y.
    Guo, Y.
    Li, Y.
    Liu, Z.
    Gong, Y.
    Wang, Y.
    Li, W.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [26] Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure
    Feng, Y.
    Zhu, H.
    Hu, X.
    Liu, Y.
    Xing, P.
    Wang, H.
    Ji, X.
    Dai, Z.
    Shi, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S609 - S609
  • [27] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
    He, Y.
    Zhao, C.
    Li, X.
    Ren, S.
    Jiang, T.
    Zhang, J.
    Su, C.
    Chen, X.
    Cai, W.
    Gao, G.
    Li, W.
    Wu, F.
    Li, J.
    Zhao, J.
    Zhou, F.
    Hu, Q.
    Hirsch, F. R.
    Zhou, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970
  • [28] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
    Zhang, H.
    Cun, F. S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
  • [29] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie P. L.
    Low, Yi Fen
    Lai, Gillianne G. Y.
    Chan, Landon L.
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia H.
    Seet, Amanda O. L.
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan -Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren W. T.
    Tan, Daniel S. W.
    Mok, Tony S. K.
    Li, Molly S. C.
    [J]. LUNG CANCER, 2024, 193
  • [30] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie Pei Li
    Low, Yi Fen
    Lai, Gillianne
    Chan, Landon
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia
    Seet, Amanda Oon Lim
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren Wan-Teck
    Tan, Daniel Shao-Weng
    Mok, Tony S. K.
    Li, Molly Sc
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345